Jereczek-Fossa B, Jassem J, Nowak R, Badzio A
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland.
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):329-38. doi: 10.1016/s0360-3016(98)00050-9.
To evaluate the incidence and risk factors for late complications after postoperative radiotherapy in endometrial cancer patients.
We performed a detailed retrospective analysis of 317 endometrial cancer patients given postoperative radiotherapy. A total of 247 patients (78%) received both intracavitary (BRT) and external beam irradiation (XRT); 49 patients (15%) received only BRT, and 21 (7%) only XRT. BRT included radium (Ra) and cesium (Cs). The mean dose rate for both isotopes at 0.5 cm from the applicator surface was 0.47 +/- 0.06 and 1.42 +/- 0.41 Gy/h, and the mean total dose was 50.5 +/- 10.3 and 48.4 +/- 15.0 Gy, respectively. Mean BRT dose at 0.5 cm was 50.1 +/- 11.7 Gy (range 14.5-71.0). Mean XRT dose in the International Commission on Radiation Units and Measurements (ICRU) reference point was 49.0 +/- 3.7 Gy (range 22.0-66.0) given in fractions of 1.54-2.49 Gy (mean 2.0 +/- 0.17) with a two- or four-field technique. Follow-up ranged from 4 to 21 years (median 7.3). Normalized total dose (NTD) including XRT and BRT doses was calculated based on a linear quadratic equation.
Five-year overall survival rate was 75%, and 5-year disease-free survival (censored for noncancer deaths) was 81%. Late radiotherapy complications of any grade occurred in 158 patients (51%), including bowel complications in 41% and urinary bladder complications in 21%. A total of 37 grade 3 or 4 complications were observed in 33 patients (11%), of whom 32 were treated with both XRT and BRT. Severe bowel and/or urinary bladder complications occurred in 24 patients: in 14 of 72 patients (19.4%) who received XRT and Cs BRT, and in 10 of 172 patients (6.0%) applied XRT and Ra BRT. The higher proportion of severe bowel and/or bladder complications in the former group was due to the particularly frequent rate of these events (30.0%) in a subset of 47 patients who received XRT combined with Cs BRT at the dose rate of 1.7 Gy/h and the total BRT dose of 60 Gy. Higher NTD, XRT fraction dose, BRT dose rate, Cs BRT, two-field XRT technique, short overall radiotherapy time, and older age were correlated with increased late-event risk in univariate analysis. Multivariate Cox analysis demonstrated that the independent risk factors for late bowel complications were NTD (p = 0.000) and BRT dose rate (p = 0.036), whereas for bladder complications they were BRT dose rate (p = 0.005) and XRT fraction dose (p = 0.041). Neither clinical factor (age, parity, prior abdominal surgery, FIGO stage, diabetes mellitus, or hypertension) nor the surgery-to-radiotherapy interval, nor overall radiotherapy time was independently associated with the risk of late bladder or bowel complications.
The risk of late complications after postoperative radiotherapy in endometrial cancer depends mainly on treatment-related factors: NTD, BRT dose rate, and XRT fraction dose. The use of combined XRT and BRT increases the risk of late effects. NTD calculations including BRT dose rate and XRT fraction dose enable estimation of radiobiologically equivalent dose and can decrease the risk of mistakes when the radiotherapy regimen is changed.
评估子宫内膜癌患者术后放疗后晚期并发症的发生率及危险因素。
我们对317例行术后放疗的子宫内膜癌患者进行了详细的回顾性分析。共有247例患者(78%)接受了腔内放疗(BRT)和外照射放疗(XRT);49例患者(15%)仅接受BRT,21例患者(7%)仅接受XRT。BRT包括镭(Ra)和铯(Cs)。两种同位素在距施源器表面0.5 cm处的平均剂量率分别为0.47±0.06和1.42±0.41 Gy/h,平均总剂量分别为50.5±10.3和48.4±15.0 Gy。距0.5 cm处的平均BRT剂量为50.1±11.7 Gy(范围14.5 - 71.0)。国际辐射单位与测量委员会(ICRU)参考点处的平均XRT剂量为49.0±3.7 Gy(范围22.0 - 66.0),采用1.54 - 2.49 Gy(平均2.0±0.17)的分次剂量,采用两野或四野技术。随访时间为4至21年(中位时间7.3年)。基于线性二次方程计算包括XRT和BRT剂量的归一化总剂量(NTD)。
5年总生存率为75%,5年无病生存率(因非癌症死亡进行截尾)为81%。158例患者(51%)发生了任何级别的晚期放疗并发症,其中肠道并发症占41%,膀胱并发症占21%。33例患者(11%)共观察到37例3级或4级并发症,其中32例接受了XRT和BRT治疗。24例患者发生了严重的肠道和/或膀胱并发症:在接受XRT和Cs BRT的72例患者中有14例(19.4%),在接受XRT和Ra BRT的172例患者中有10例(6.0%)。前一组中严重肠道和/或膀胱并发症比例较高是由于在47例接受剂量率为1.7 Gy/h的XRT联合Cs BRT且BRT总剂量为60 Gy的亚组中这些事件发生率特别高(30.0%)。在单因素分析中,较高的NTD、XRT分次剂量、BRT剂量率、Cs BRT、两野XRT技术、较短的总放疗时间和较高年龄与晚期事件风险增加相关。多因素Cox分析表明,晚期肠道并发症的独立危险因素是NTD(p = 0.000)和BRT剂量率(p = 0.036),而膀胱并发症的独立危险因素是BRT剂量率(p = 0.005)和XRT分次剂量(p = 0.041)。临床因素(年龄、产次、既往腹部手术、国际妇产科联盟(FIGO)分期、糖尿病或高血压)、手术至放疗间隔以及总放疗时间均与晚期膀胱或肠道并发症风险无独立相关性。
子宫内膜癌术后放疗后晚期并发症的风险主要取决于与治疗相关的因素:NTD、BRT剂量率和XRT分次剂量。联合使用XRT和BRT会增加晚期效应的风险。包括BRT剂量率和XRT分次剂量的NTD计算能够估算放射生物学等效剂量,并可在放疗方案改变时降低出错风险。